RecruitingPhase 1NCT06974877
Immune
Cryopyrin-Associated Periodic Syndromes
Also known as CAPS, TRAPS, Muckle-Wells syndrome, NOMID
Cryopyrin-Associated Periodic Syndromes represent a spectrum of autoinflammatory disorders caused by gain-of-function mutations in NLRP3 encoding cryopyrin, an inflammasome component that drives pathological IL-1 beta overproduction, rangin
ORPHA:425 ↗Gene NLRP3Gene TNFRSF1APrevalence CAPS: 1-2 in 1,000,000; TRAPS: 1 in 1,000,000Onset Infancy to early childhood for CAPS; any age for TRAPSAutoinflammatory periodic fever syndrome (inflammasomopathy)
5
studies recruiting now
as of 7 Sept 2026
37
studies registered in total
as of 7 Sept 2026
4
countries with a recruiting site
as of 7 Sept 2026
25 Nov 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT06838143
Ilaris NIS in Korea
RecruitingNCT02974595
Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
RecruitingNot applicableNCT06544018
Circadian Rhythm Deregulation in Patients With CAPS
RecruitingPhase 1NCT07247266
Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Cryopyrin-Associated Periodic Syndromes studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Cryopyrin-Associated Periodic Syndromes study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: Eurofever Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Cryopyrin-Associated Periodic Syndromes
Cryopyrin-Associated Periodic Syndromes represent a spectrum of autoinflammatory disorders caused by gain-of-function mutations in NLRP3 encoding cryopyrin, an inflammasome component that drives pathological IL-1 beta overproduction, ranging in severity from the mild cold-triggered urticaria of FCAS to the chronic devastating multisystem inflammation of NOMID/CINCA syndrome. TNF Receptor-Associated Periodic Syndrome (TRAPS) is caused by TNFRSF1A mutations and is included in this grouping as a related periodic fever syndrome with overlapping phenotypic features. IL-1 inhibition with anakinra, canakinumab, or rilonacept has transformed outcomes in CAPS, while TRAPS is primarily managed with IL-1 or TNF blockade.
Common clinical features
Recurrent urticarial rash (non-pruritic, cold-triggered in FCAS)Fever and systemic inflammation during attacksSensorineural hearing loss (Muckle-Wells, NOMID)Chronic meningitis and elevated intracranial pressure (NOMID)Joint deformities and epiphyseal overgrowth (NOMID)Uveitis and papilledemaAA amyloidosis with renal involvement in untreated disease
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Cryopyrin-Associated Periodic Syndromes. Not eligibility rules; those are set by each study.
- Molecular confirmation of NLRP3 or TNFRSF1A pathogenic variant is required for most trials; somatic mosaic mutations may be present and require sensitive sequencing methods if standard testing is negative
- Anakinra and canakinumab trials for CAPS typically require minimum C-reactive protein or SAA elevation at screening; ensure assessments are performed off anti-IL-1 therapy during washout
- Pediatric and adult arms are often separate; confirm age cutoffs and weight thresholds (especially for somatic NOMID patients with growth delay)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).